1522 related articles for article (PubMed ID: 18579534)
1. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
[TBL] [Abstract][Full Text] [Related]
2. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephron Clin Pract; 2008; 110(1):c58-65. PubMed ID: 18724068
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D deficiency and associated factors in hemodialysis patients.
Jean G; Charra B; Chazot C
J Ren Nutr; 2008 Sep; 18(5):395-9. PubMed ID: 18721733
[TBL] [Abstract][Full Text] [Related]
4. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation.
Jean G; Souberbielle JC; Chazot C
Nephrol Dial Transplant; 2009 Dec; 24(12):3799-805. PubMed ID: 19622574
[TBL] [Abstract][Full Text] [Related]
5. On-line haemodiafiltration improves response to calcifediol treatment.
Pérez-García R; Albalate M; de Sequera P; Alcázar R; Puerta M; Ortega M; Corchete E
Nefrologia; 2012 Jul; 32(4):459-66. PubMed ID: 22652556
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients.
Blair D; Byham-Gray L; Lewis E; McCaffrey S
J Ren Nutr; 2008 Jul; 18(4):375-82. PubMed ID: 18558303
[TBL] [Abstract][Full Text] [Related]
7. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
8. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
[TBL] [Abstract][Full Text] [Related]
9. Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in hemodialysis patients.
Fiedler R; Deuber HJ; Langer T; Osten B; Mohan S; Jehle PM
Nephron Clin Pract; 2004; 96(1):c3-9. PubMed ID: 14752247
[TBL] [Abstract][Full Text] [Related]
10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
11. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients.
Tokmak F; Quack I; Schieren G; Sellin L; Rattensperger D; Holland-Letz T; Weiner SM; Rump LC
Nephrol Dial Transplant; 2008 Dec; 23(12):4016-20. PubMed ID: 18593741
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis.
Del Valle E; Negri AL; Aguirre C; Fradinger E; Zanchetta JR
Hemodial Int; 2007 Jul; 11(3):315-21. PubMed ID: 17576296
[TBL] [Abstract][Full Text] [Related]
13. Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens.
Minisola S; Cianferotti L; Biondi P; Cipriani C; Fossi C; Franceschelli F; Giusti F; Leoncini G; Pepe J; Bischoff-Ferrari HA; Brandi ML
Osteoporos Int; 2017 Nov; 28(11):3239-3249. PubMed ID: 28815282
[TBL] [Abstract][Full Text] [Related]
14. Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients.
Alghareeb A; Sabry A; Bawadekji H; Alsaran K
Ther Apher Dial; 2013 Feb; 17(1):30-4. PubMed ID: 23379490
[TBL] [Abstract][Full Text] [Related]
15. Markers of bone remodeling in the elderly subject: effects of vitamin D insufficiency and its correction.
Brazier M; Kamel S; Maamer M; Agbomson F; Elesper I; Garabedian M; Desmet G; Sebert JL
J Bone Miner Res; 1995 Nov; 10(11):1753-61. PubMed ID: 8592953
[TBL] [Abstract][Full Text] [Related]
16. Risk in dosing regimens for 25-OH vitamin D supplementation in chronic haemodialysis patients.
Albalate M; de la Piedra C; Ortiz A; Hernández Pérez J; Rubert M; Pérez Garcia R; Zazo P; Nieto L; de Sequera P; Egido J
Nephron Clin Pract; 2012; 121(3-4):c112-9. PubMed ID: 23221739
[TBL] [Abstract][Full Text] [Related]
17. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
18. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
Reichel H
Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
[TBL] [Abstract][Full Text] [Related]
19. Effect of vitamin D supplementation on vitamin D status and bone turnover markers in young adults.
Barnes MS; Robson PJ; Bonham MP; Strain JJ; Wallace JM
Eur J Clin Nutr; 2006 Jun; 60(6):727-33. PubMed ID: 16391584
[TBL] [Abstract][Full Text] [Related]
20. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.
Matias PJ; Jorge C; Ferreira C; Borges M; Aires I; Amaral T; Gil C; Cortez J; Ferreira A
Clin J Am Soc Nephrol; 2010 May; 5(5):905-11. PubMed ID: 20203163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]